ELIPSe is a national Health Information Management (HIM) and revenue cycle consultancy specializing in organization-wide ICD-10 assessment and implementation, ICD-9, CPT, and ICD-10 coding education and training, interim HIM management, HIM operations assessment, RAC/coding/billing audits, Charge Description Master review, DNFB (Discharged Not Final Billed) reduction solutions, interim coding management, and Master Patient Index (MPI) remediation and cleanup.
ELIPSe's Product Videos
ELIPSe's Products & Differentiators
Automated scheduling solution through AI using communication channels such as Voicebot, WhatsAppbot, Chatbot and web agenda.
Latest ELIPSe News
Oct 31, 2022
Allurion has received approval from the Brazilian Health Regulatory Agency (ANVISA) to launch its Elipse Balloon, the world’s first and only procedureless gastric balloon, in Brazil. The Allurion swallowable gastric balloon comes as part of the Allurion Program, which supports patients to make positive lifestyle changes that result in long-term weight loss. The holistic program includes support from a doctor and nutritionist, as well as a suite of digital tools designed to help maximise success. Dr Eduardo Grecco, a gastric surgeon and endoscopist at Instituto Endovitta in São Paulo, Brazil, welcomed an additional tool to help fight obesity: “According to Secretária de Vigilância em Saúde, our local health surveillance agency, around 20% of the adult population is currently living with obesity and an additional 36% are overweight. That is almost 95 million people. We have seen an 80% increase in obesity in the past 10 years – especially among 25- to 45-year-olds. That has a knock-on effect on other conditions for which obesity is a major risk factor.” Dr. Manoel Galvao Neto, head of bariatric endoscopy of Mohak Bariatric and Robotics and scientific director at Instituto Endovitta, agrees. “It really is important that we act now to help these people lose weight. Having tools such as the Allurion Program at our disposal will be a game-changer.” The Allurion Program is intended for people who are unable to achieve their weight-loss goals by dieting alone, and those who do not want to – or cannot – undergo invasive surgery or endoscopy. It may also be suitable for people who need to manage weight-related co-morbidities, such as diabetes, infertility, or cardiovascular disease. The prevalence of obesity in Brazil has increased from 11.8% in 2006 to 20.3% in 2019. By 2030, nearly 30% of Brazil’s adult population will have obesity. As a result, Allurion estimates a total addressable market of around 1.3 million consumers in Brazil who would be eligible for and would consider choosing the Allurion Program. Dr Shantanu Gaur, Co-Founder and CEO of Allurion, said the need to address obesity in Brazil is more urgent than ever: “Obesity represents one of the most significant health challenges in Brazil today. We welcome ANVISA’s approval, and we look forward to working with healthcare professionals and other weight-loss experts to end obesity in the country.” Benoit Chardon, Chief Commercial Officer at Allurion, said the approval was just the latest move for the company into markets where obesity was a serious health challenge: “We are confident in our future success in Brazil, because we have three major advantages: the revolutionary, procedureless nature of our device, the comprehensive nature of our program which includes an AI-powered remote patient monitoring system and behavior change program that complements the device, and the experience we have assembled after treating over 100,000 patients around the world.” The Allurion Program is available in five clinics in Brazil, with seven more to open soon. As with other markets, Chardon says Allurion will be selective at first in partnering with clinics to offer the program: “We want to guarantee best-in-class experience for all our patients: only the most experienced teams and clinics will be trained to deliver this sophisticated program.” The company has demonstrated clear product-market fit in over 50 countries to date and has grown top-line revenues by 100% year-over-year for the past 6 years. With launches this year in Australia, Canada, Mexico, India, and now Brazil, the company has nearly doubled its footprint in just the past 12 months. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Gastric Balloon, the world’s first and only swallowable, procedureless1 gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for clinicians featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion VCS is now available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.
ELIPSe Frequently Asked Questions (FAQ)
Where is ELIPSe's headquarters?
ELIPSe's headquarters is located at 11901 Santa Monica Blvd, Los Angeles.
What is ELIPSe's latest funding round?
ELIPSe's latest funding round is Acquired.
Who are the investors of ELIPSe?
Investors of ELIPSe include Xtend Healthcare.
Who are ELIPSe's competitors?
Competitors of ELIPSe include VoxImplant.
What products does ELIPSe offer?
ELIPSe's products include Omnichannel scheduling and 2 more.
Who are ELIPSe's customers?
Customers of ELIPSe include UC Christus, Integramédica, Novo Nordisk, Sura and Salud Total.
Compare ELIPSe to Competitors
Vozy operates as a voice communication platform. It offers voice assistants and conversational artificial intelligence (AI) solutions that help companies interact with their customers and improves their customer experience. It was founded in 2016 and is based in Miami, Florida.
Cognigy provides enterprise software for conversational artificial intelligence automation. It offers products that include voice gateway, conversational interactive voice response (IVR) , and more. It also offers solutions that include customer service automation, workforce management, enterprise conversational artificial intelligence-based solutions, and others. It caters to industries such as insurance, e-commerce, airlines, and others. The company was founded in 2016 and is based in Dusseldorf, Germany.
Talkdesk provides artificial intelligence (AI) based cloud call center platform. It improves customer interactions across a variety of channels, including phone, email, chat, and social media. It serves industries such as financial services, retail, healthcare, and more. The company was founded in 2011 and is based in San Francisco, California.
EVE calls help to scale top-performing sales and service team members with the most natural engaging artificial intelligence voice platform on the market. It offers services for lead generation, debt collection, loyalty measurement and surveys, and more. The company was founded in 2016 and is based in Boston, Massachusetts.
VoxImplant is a platform for real-time communication application development. It allows mobile and web developers to embed audio, video, and instant messaging into the applications in minutes. It was formerly known as Zingaya. It was founded in 2008 and is based in New York, New York.
Plivo is a cloud communication platform that offers a way for companies to integrate voice and SMS capabilities into their applications.